Are trifluridine, tipiracil (Lancever) and tas-102 the same drug?

Trifluridine tipiracil (Lonsurf/Lonsurf) and TAS-102 are different names for the same drug, but different names are used in different countries or regions. The drug is an oral chemotherapy drug that is particularly effective in fighting digestive system tumors, such as colorectal and stomach cancers.

Trifluridine and tipiracil are composed of two main ingredients: trifluridine (trifluridine) and tipiracil. Trifluridine and tipiracil are nucleoside analogs that can be taken up by tumor cells and embedded into DNA chains, interfering with the DNA synthesis process, thereby causing tumor cell death. However, trifluridine is easily broken down by uridine kinase, so the addition of tipiracil can effectively improve the stability and bioavailability of trifluridine in the body.

The efficacy of trifluridine and tipiracil has been confirmed in multiple clinical trials. The use of a specific medication regimen, that is, continuous administration twice a day A cyclic therapy of 5 days followed by 2 days of rest, can achieve significant disease control rates in a variety of malignant tumors. Studies have shown that compared with traditional chemotherapy regimens, trifluridine and tipiracil can significantly prolong the overall survival of patients with advanced colorectal cancer, reduce symptoms, and improve quality of life. In addition, trifluridine and tipiracil have also been shown to have certain efficacy in patients with strong drug resistance or intolerance to other chemotherapy drugs.

However, trifluridine and tipiracil may also cause some side effects, including bone marrow suppression, nausea, vomiting, diarrhea, fatigue, and loss of appetite. Therefore, when using this drug, doctors will evaluate and adjust the dose based on the patient's specific situation and closely monitor the patient's physical condition.